Research Analysts Set Expectations for PMN Q2 Earnings

Promis Neurosciences (NASDAQ:PMN) – Brookline Capital Markets issued their Q2 2026 earnings per share (EPS) estimates for Promis Neurosciences in a research note issued on Wednesday, May 20th. Brookline Capital Markets analyst F. Ahmed forecasts that the company will post earnings of ($2.09) per share for the quarter. Brookline Capital Markets currently has a “Strong-Buy” rating on the stock. Brookline Capital Markets also issued estimates for Promis Neurosciences’ Q3 2026 earnings at ($2.41) EPS, Q4 2026 earnings at ($2.44) EPS, Q1 2027 earnings at ($2.32) EPS, Q2 2027 earnings at ($1.02) EPS, Q3 2027 earnings at ($1.15) EPS and Q4 2027 earnings at ($0.98) EPS.

Promis Neurosciences (NASDAQ:PMN) last issued its earnings results on Tuesday, May 12th. The company reported ($1.26) earnings per share for the quarter, missing the consensus estimate of ($1.06) by ($0.20).

Several other equities research analysts have also recently issued reports on PMN. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Promis Neurosciences in a research report on Thursday, January 22nd. Wall Street Zen lowered Promis Neurosciences to a “strong sell” rating in a report on Saturday, February 14th. Finally, Guggenheim decreased their price target on Promis Neurosciences from $125.00 to $35.00 and set a “buy” rating for the company in a report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $26.50.

Promis Neurosciences Stock Up 2.4%

NASDAQ PMN opened at $10.85 on Friday. Promis Neurosciences has a 52 week low of $6.27 and a 52 week high of $39.75. The firm has a 50 day moving average of $13.00 and a two-hundred day moving average of $12.00. The stock has a market capitalization of $97.32 million, a PE ratio of -0.75 and a beta of -0.20.

Insider Buying and Selling at Promis Neurosciences

In other Promis Neurosciences news, Director Patrick D. Kirwin acquired 4,000 shares of the company’s stock in a transaction on Wednesday, April 22nd. The shares were bought at an average cost of $11.33 per share, for a total transaction of $45,320.00. Following the completion of the purchase, the director owned 4,653 shares in the company, valued at $52,718.49. This trade represents a 612.56% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Eugene Williams bought 2,000 shares of Promis Neurosciences stock in a transaction dated Wednesday, March 4th. The stock was acquired at an average cost of $24.00 per share, with a total value of $48,000.00. Following the completion of the acquisition, the director directly owned 12,397 shares of the company’s stock, valued at approximately $297,528. The trade was a 19.24% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 7,000 shares of company stock worth $115,850 over the last three months. 1.50% of the stock is currently owned by insiders.

Institutional Trading of Promis Neurosciences

A number of hedge funds have recently added to or reduced their stakes in the stock. Ally Bridge Group NY LLC grew its stake in shares of Promis Neurosciences by 367.1% in the 3rd quarter. Ally Bridge Group NY LLC now owns 6,233,497 shares of the company’s stock valued at $2,649,000 after purchasing an additional 4,899,069 shares during the last quarter. Citadel Advisors LLC raised its stake in shares of Promis Neurosciences by 168.1% during the third quarter. Citadel Advisors LLC now owns 170,079 shares of the company’s stock worth $72,000 after purchasing an additional 106,650 shares during the last quarter. Armistice Capital LLC raised its stake in shares of Promis Neurosciences by 39.1% during the third quarter. Armistice Capital LLC now owns 2,974,518 shares of the company’s stock worth $1,264,000 after purchasing an additional 836,622 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in shares of Promis Neurosciences during the first quarter worth $1,211,000. Finally, Yu Fan purchased a new position in Promis Neurosciences in the 1st quarter valued at $4,188,000. 50.13% of the stock is owned by institutional investors and hedge funds.

Promis Neurosciences Company Profile

Promis Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.